Significant alterations in miRNAs that control autophagy and inflammation genes are observed in PD progression, while nilotinib, targets DDR1 and reverses these miRNA levels, in agreement with the preclinical effects of nilotinib on the molecular pathways of autophagy and inflammation [21,22,23,29,30,31,32,33]. Here, DDR1 is linked to Parkinson disease.